CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0359 (clinicaltrials.gov NCT No: NCT01348490)
Title:AN OPEN LABEL ASSESSMENT OF SAFETY AND EFFICACY OF RUXOLITINIB IN SUBJECTS WITH PRIMARY MYELOFIBROSIS, POST ESSENTIAL THROMBOCYTHEMIAMYELOFIBROSIS AND POST POLYCYTHEMIA VERAMYELOFIBROSIS WHO HAVE PLATELET COUNTS OF 50 x10^9/L TO 100 x10^9/L
Principal Investigator:Srdan Verstovsek
Treatment Agent:Ruxolitinib
Study Status:Closed
Study Description:Unavailable

Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase II
Treatment Agents:Ruxolitinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:lncyte Corporation
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Srdan Verstovsek
Dept:Leukemia
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults